News >

Ruxolitinib Hits Primary Endpoint in Phase III Acute GVHD Trial

OncLive Staff
Published: Wednesday, Oct 16, 2019

Peter Langmuir, MD, group vice president, Targeted Therapies, Incyte

Peter Langmuir, MD

Ruxolitinib (Jakafi) met the primary endpoint of the phase III REACH2 trial, improving the overall response rate at day 28 versus best available therapy in patients with in patients with steroid-refractory acute graft-versus-host disease (aGVHD).1

Ruxolitinib is also approved by the FDA as a treatment for patients with polycythemia vera who are intolerant of or have an inadequate response to hydroxyurea, as well as for the treatment of patients with intermediate or high-risk myelofibrosis.

References         

  1. Incyte announces that the REACH2 pivotal trial of ruxolitinib (Jakafi®) meets primary endpoint in patients with steroid-refractory acute graft-versus-host disease. Published October 16, 2019. Accessed October 16, 2019. https://bit.ly/2MLIJZR.  
  2. FDA approves Jakafi (ruxolitinib) for the treatment of patients with acute graft-versus-host disease. Incyte. Published May 24, 2019. Accessed October 16, 2019. https://bit.ly/2WiRktX.
  3. Jagasia M, Perales M-A, Schroeder MA, et al. Results from REACH1, a single-arm phase 2 study of ruxolitinib in combination with corticosteroids for the treatment of steroid-refractory acute graft-vs-host disease. Presented at: 2018 ASH Annual Meeting; December 1-4, 2018; San Diego, CA. Abstract 601.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x